An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

  • End date
    Dec 4, 2022
  • participants needed
  • sponsor
Updated on 21 February 2021
Clinical Trials Registry Team
Primary Contact
Fundaci n de Investigaci n de Diego (1.8 mi away) Contact
+79 other location
crohn's disease


This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy

Condition Inflammatory bowel disease, Crohn's Disease, Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome (IBS- Pediatric), Crohn's Disease (Pediatric), ibudilast, inflammatory bowel diseases, crohns disease
Treatment Placebo, Humira®, Brazikumab low dose, Brazikumab high dose
Clinical Study IdentifierNCT03759288
Last Modified on21 February 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note